{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:48:18Z","timestamp":1792439298141,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017255","name":"Allergy Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaip.2019.02.030","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T17:11:30Z","timestamp":1553706690000},"page":"1418-1429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Marc","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kottakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.02.030_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mrfmmm.2009.09.005","article-title":"Chronic inflammation and asthma","volume":"690","author":"Murdoch","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.jaip.2019.02.030_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaip.2014.09.004","article-title":"The allergic asthma phenotype","volume":"2","author":"Schatz","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.030_bib3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/all.12637","article-title":"Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis","volume":"70","author":"Bousquet","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S2213-2600(13)70277-7","article-title":"Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study","volume":"2","author":"Pinart","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib5","doi-asserted-by":"crossref","first-page":"e2012006","DOI":"10.5620\/eht.2012.27.e2012006","article-title":"The prevalence of atopic dermatitis, asthma, and allergic rhinitis and the comorbidity of allergic diseases in children","volume":"27","author":"Hong","year":"2012","journal-title":"Environ Health Toxicol"},{"key":"10.1016\/j.jaip.2019.02.030_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41533-017-0026-x","article-title":"High probability of comorbidities in bronchial asthma in Germany","volume":"27","author":"Heck","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaip.2017.06.007","article-title":"Asthma morbidity, comorbidities, and modifiable factors among older adults","volume":"6","author":"Hsu","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.030_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","article-title":"Asthma control and disease burden in patients with asthma and allergic comorbidities","volume":"55","author":"Lee","year":"2018","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.02.030_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.rmed.2016.05.008","article-title":"Comorbidities of asthma in U.S. children","volume":"116","author":"Mirabelli","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib10","doi-asserted-by":"crossref","first-page":"e3459","DOI":"10.1097\/MD.0000000000003459","article-title":"Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis","volume":"95","author":"Su","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2019.02.030_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/pai.12241","article-title":"Asthma with allergic comorbidities in adolescence is associated with bronchial responsiveness and airways inflammation","volume":"25","author":"Hovland","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/resp.13026","article-title":"Co-morbidities in severe asthma: clinical impact and management","volume":"22","author":"Porsbjerg","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2019.02.030_bib13","doi-asserted-by":"crossref","first-page":"819194","DOI":"10.1155\/2015\/819194","article-title":"Chronic comorbidities contribute to the burden and costs of persistent asthma","volume":"2015","author":"Kauppi","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaip.2019.02.030_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MCP.0b013e32835b113a","article-title":"Comorbidities of asthma: current knowledge and future research needs","volume":"19","author":"Cazzola","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cea.12897","article-title":"The sensitization pattern differs according to rhinitis and asthma multimorbidity in adults: the EGEA study","volume":"47","author":"Burte","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1398-9995.2010.02534.x","article-title":"MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib17","first-page":"202","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"5","author":"Bantz","year":"2014","journal-title":"J\u00a0Clin Cell Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaci.2016.12.940","article-title":"Mechanisms of the Development of Allergy (MeDALL): introducing novel concepts in allergy phenotypes","volume":"139","author":"Anto","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib20","doi-asserted-by":"crossref","first-page":"E1328","DOI":"10.3390\/ijms18061328","article-title":"dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies","volume":"18","author":"Palomares","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2019.02.030_bib21","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib22","first-page":"8163803","article-title":"IgE-related chronic diseases and anti-IgE-based treatments","volume":"2016","author":"Navines-Ferrer","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jaip.2019.02.030_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI8205","article-title":"IgE in asthma and atopy: cellular and molecular connections","volume":"104","author":"Oettgen","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2019.02.030_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.iac.2006.02.004","article-title":"IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy","volume":"26","author":"Wilcock","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.02.030_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1399-3038.2010.00993.x","article-title":"Sensitization patterns to food and inhalant allergens in childhood: a comparison of non-sensitized, monosensitized, and polysensitized children","volume":"22","author":"de Jong","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-7022-4-16","article-title":"Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease","volume":"4","author":"Migueres","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/resp.12838","article-title":"Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life","volume":"21","author":"Tay","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2019.02.030_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03007995.2017.1380617","article-title":"Moving toward consensus on diagnosis and management of severe asthma in adults","volume":"34","author":"Colodenco","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2019.02.030_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/ACI.0b013e32835c16b6","article-title":"Asthma and comorbidities","volume":"13","author":"Ledford","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5415\/apallergy.2011.1.3.157","article-title":"Overview on the pathomechanisms of allergic rhinitis","volume":"1","author":"Pawankar","year":"2011","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1034\/j.1398-9995.2003.00105.x","article-title":"Links between rhinitis and asthma","volume":"58","author":"Bousquet","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.0105-4538.2003.00354.x","article-title":"Nasal involvement in allergic asthma","volume":"58","author":"Braunstahl","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1398-9995.2006.01226.x","article-title":"Tissue remodelling in upper airways: where is the link with lower airway remodelling?","volume":"61","author":"Watelet","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.anai.2016.09.439","article-title":"Association of severity of chronic rhinosinusitis with degree of comorbid asthma control","volume":"117","author":"Phillips","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib37","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1067\/mai.2000.110151","article-title":"Epidemiologic evidence for asthma and rhinitis comorbidity","volume":"106","author":"Leynaert","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib38","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.02.030_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0091-6749(99)70320-9","article-title":"Allergic rhinobronchitis: the asthma-allergic rhinitis link","volume":"104","author":"Simons","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1398-9995.1998.tb03988.x","article-title":"Relationships between rhinitis and asthma","volume":"53","author":"Vignola","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib41","doi-asserted-by":"crossref","first-page":"2184193","DOI":"10.1155\/2017\/2184193","article-title":"Prevalence and risk factors of asthma, rhinitis, and eczema and their multimorbidity among young adults in Kuwait: a cross-sectional study","volume":"2017","author":"Ziyab","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaip.2019.02.030_bib42","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1378\/chest.111.2_Supplement.11S","article-title":"One airway, one disease","volume":"111","author":"Grossman","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.02.030_bib43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0873-2159(15)30160-4","article-title":"The association of rhinoconjunctivitis and asthma symptoms in adolescents","volume":"15","author":"Brito Rde","year":"2009","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.jaip.2019.02.030_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib45","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2019.02.030_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib48","first-page":"5249","article-title":"Effects of omalizumab therapy on allergic rhinitis: a pilot study","volume":"20","author":"Masieri","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaip.2019.02.030_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib50","first-page":"88","article-title":"Ocular complications of vernal keratoconjunctivitis","volume":"34","author":"Tabbara","year":"1999","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jaip.2019.02.030_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/pai.12197","article-title":"Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes","volume":"25","author":"Vichyanond","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaip.2019.02.030_bib53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","article-title":"Omalizumab. An option in vernal keratoconjunctivitis?","volume":"40","author":"S\u00e1nchez","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaip.2019.02.030_bib54","first-page":"305","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaip.2019.02.030_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jaip.2019.02.030_bib56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/pai.12350","article-title":"Vernal Keratoconjunctivitis and immune-mediated diseases: one unique way to symptom control?","volume":"26","author":"Occasi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2019.02.030_bib58","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib59","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1398-9995.2011.02709.x","article-title":"Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe","volume":"67","author":"Jarvis","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1067\/mai.2002.122458","article-title":"Chronic sinusitis in severe asthma is related to sputum eosinophilia","volume":"109","author":"ten Brinke","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib62","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2016.06.066","article-title":"Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps","volume":"139","author":"Chen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaci.2010.07.007","article-title":"Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma","volume":"126","author":"Bachert","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2017.05.004","article-title":"The IL-33\/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D","volume":"141","author":"Teufelberger","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.2012.02559.x","article-title":"Chronic rhinosinusitis and asthma: novel understanding of the role of IgE \"above atopy\"","volume":"272","author":"Bachert","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jaci.2016.03.045","article-title":"Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus","volume":"139","author":"Stentzel","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jprot.2017.01.008","article-title":"Characterization of human and Staphylococcus aureus proteins in respiratory mucosa by in\u00a0vivo- and immunoproteomics","volume":"155","author":"Schmidt","year":"2017","journal-title":"J\u00a0Proteomics"},{"key":"10.1016\/j.jaip.2019.02.030_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib70","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0091-6749(03)70044-X","article-title":"IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma","volume":"111","author":"Bachert","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib72","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/thx.2010.152835","article-title":"Efficacy of omalizumab in the treatment of nasal polyps","volume":"66","author":"Vennera Mdel","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2019.02.030_bib73","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","article-title":"The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study","volume":"21","author":"Penn","year":"2007","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jaip.2019.02.030_bib74","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2500\/aap2007.28.3048","article-title":"Atopic dermatitis and asthma","volume":"28","author":"Galli","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.030_bib75","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.111.3.608","article-title":"Atopic dermatitis and asthma: parallels in the evolution of treatment","volume":"111","author":"Eichenfield","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2019.02.030_bib76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaci.2007.05.042","article-title":"Risk of developing asthma in young children with atopic eczema: a systematic review","volume":"120","author":"van der Hulst","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2500\/ar.2016.7.0144","article-title":"The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis","volume":"7","author":"Celakovsk\u00e1","year":"2016","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.jaip.2019.02.030_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib79","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaip.2019.02.030_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ijd.13353","article-title":"Omalizumab for atopic dermatitis: case series and a systematic review of the literature","volume":"56","author":"Holm","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2019.02.030_bib81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13063-017-1809-7","article-title":"Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial","volume":"18","author":"Chan","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jaip.2019.02.030_bib82","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","article-title":"Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study","volume":"29","author":"Sheinkopf","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.030_bib83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2017.07.004","article-title":"Immunology of food allergy","volume":"47","author":"Tordesillas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2019.02.030_bib84","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1398-9995.2007.01425.x","article-title":"The prevalence, cost and basis of food allergy across Europe","volume":"62","author":"Mills","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/all.12341","article-title":"The prevalence and distribution of food sensitization in European adults","volume":"69","author":"Burney","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/all.12585","article-title":"The EuroPrevall outpatient clinic study on food allergy: background and methodology","volume":"70","author":"Fern\u00e1ndez-Rivas","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/all.12868","article-title":"Prevalence of food sensitization and probable food allergy among adults in India: the EuroPrevall INCO study","volume":"71","author":"Mahesh","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/ACI.0b013e3283464c8e","article-title":"Food allergies and asthma","volume":"11","author":"Wang","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib89","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4161\/hv.29233","article-title":"Oral immunotherapy for the treatment of food allergy","volume":"10","author":"Begin","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaip.2019.02.030_bib90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.iac.2011.11.004","article-title":"Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy","volume":"32","author":"Nadeau","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.02.030_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40413-015-0070-3","article-title":"Oral immunotherapy and anti-IgE antibody treatment for food allergy","volume":"8","author":"Umetsu","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2019.02.030_bib92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2019.02.030_bib93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00005-016-0420-z","article-title":"The use of omalizumab in food oral immunotherapy","volume":"65","author":"Labrosse","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jaip.2019.02.030_bib94","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaci.2017.03.028","article-title":"Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy","volume":"140","author":"Frischmeyer-Guerrerio","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib95","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2500\/aap.2010.31.3304","article-title":"Effects of omalizumab in patients with food allergy","volume":"31","author":"Rafi","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.030_bib97","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib98","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib99","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib100","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A\u00a0pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib101","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.030_bib102","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4168\/aair.2016.8.4.282","article-title":"Allergic bronchopulmonary aspergillosis: a perplexing clinical entity","volume":"8","author":"Shah","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2019.02.030_bib103","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.02.030_bib104","first-page":"936","article-title":"Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis","volume":"13","author":"Agarwal","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaip.2019.02.030_bib105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaip.2016.03.010","article-title":"Allergic fungal rhinosinusitis","volume":"4","author":"Hoyt","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.030_bib106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib107","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases","volume":"36","author":"Aydin","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.030_bib108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.030_bib109","first-page":"S29","article-title":"Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody","volume":"27","author":"Berger","year":"2006","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.030_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11882-010-0173-4","article-title":"Omalizumab: Anti-IgE therapy in allergy","volume":"11","author":"Kopp","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2019.02.030_bib111","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12889-015-1733-2","article-title":"The increasing burden and complexity of multimorbidity","volume":"15","author":"Pefoyo","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jaip.2019.02.030_bib112","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.05.015","article-title":"Approaches to target IgE antibodies in allergic diseases","volume":"191","author":"Balbino","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaip.2019.02.030_bib113","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.02.030_bib114","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/qjmed\/hcw027","article-title":"Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study","volume":"109","author":"Cusack","year":"2016","journal-title":"QJM"},{"key":"10.1016\/j.jaip.2019.02.030_bib115","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1183\/13993003.01501-2015","article-title":"Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma","volume":"48","author":"Pillai","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.02.030_bib116","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A\u00a0proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819302454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819302454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:51Z","timestamp":1761974331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819302454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2213219819302454"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.030","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}